Evidence map›Paper›PMID 38775919›Full record

ArticleMolecular imaging and biology2024

Challenges in Pharmacokinetic Modelling of [

Thomas Ruytenberg, Isabeau A Ciggaar, Inge T A Peters, Wyanne A Noortman, Petra Dibbets-Schneider, Lysanne D A N de Muynck, Joeri Kuil, Cornelis D de Kroon, Tom J M Molenaar, Hendrik J F Helmerhorst and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Dual-receptor PET imaging of ovarian cancer using aAmerican journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thomas Ruytenberg *Dept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9077-0292
Isabeau A Ciggaar *Dept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Inge T A PetersDept. Of Gynecology, Leiden University Medical Center, Leiden, The Netherlands.
Wyanne A NoortmanDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Petra Dibbets-SchneiderDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Lysanne D A N de MuynckDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Joeri KuilDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Cornelis D de KroonDept. Of Gynecology, Leiden University Medical Center, Leiden, The Netherlands.
Tom J M MolenaarDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Hendrik J F HelmerhorstDept. of Anesthesiology and Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
Lenka M Pereira Arias-BoudaDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Alexander L VahrmeijerDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Albert D WindhorstDept. of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Floris H P van VeldenDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Katja N GaarenstroomDept. Of Gynecology, Leiden University Medical Center, Leiden, The Netherlands.
Lioe-Fee de Geus-OeiDept. of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands. L.F.de_Geus-Oei@lumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the pharmacokinetic properties of the [ PROCEDURES: In five patients with advanced EOC (FIGO stage IIIB/IIIC, Fédération Internationale de Gynécologie et d'Obstétrique), a 90-min dynamic PET acquisition of the pelvis was performed directly after i.v. administration of 185 MBq [

resultsThe pharmacokinetic analysis in the pelvic area has proven to be much more challenging than expected. Only four out of 22 tumor lesions in five patients were considered suitable to perform modelling on. The remaining tumor lesions were inapt due to either low tracer uptake, small size, proximity to other [

conclusionPerforming pharmacokinetic analysis in the abdominal pelvic region is very challenging. This brief article describes the challenges and pitfalls in pharmacokinetic analysis of a tracer with high physiological accumulation in the intestines, in case of lesions of limited size in the abdominal pelvic area.

Indexed as

Carcinoma, Ovarian EpithelialFolic AcidOvarian NeoplasmsPolyethylene GlycolsPositron Emission Tomography Computed TomographyAgedFemaleFluorine RadioisotopesHumansMiddle AgedModels, BiologicalFluorine RadioisotopesFolic Acidpoly(ethylene glycol)-folatePolyethylene GlycolsDynamic PETF-18Molecular imagingOvarian cancerPET tracersPharmacokinetic modelingTracer kinetic methodology

Identifiers

PMID38775919
PMCPMC11282117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.